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Objectives: To investigate the role of lower extremity ischaemia n acute lung injury with special emphasis on the role 
of tumour necrosis factor (TNF) and nitric oxide (NO) as mediators of neutrophil (PMN) chemotaxis in the lung. 
Design: Prospective randomised study. 
Materials and methods: Sprague-Dawley rats were randomized into four groups: group 1 (x-clamp): aorta clamped 
just above the bifurcation for 3 h; group 2 (AG): 50 mg/kg aminoguanidine, a specific inducible NO synthase (iNOS) 
inhibitor, was administered prior to aortic occlusion; group 3 (Steroids): i mg/kg dexamethasone was administered prior 
to aortic occlusion; and group 4 (TNFbp): 2 mg/kg TNFbp, a PEGylated imeric form of the high affinity TNF receptor 
I (R~) was administered prior to aortic occlusion to block TNF action. Groups 2, 3 and 4 were subjected to the same 
ischaemia time as group 1. NO concentration i  the exhaled gas (ENO) was measured in 30 rain intervals. At the end 
of the 3 h ischaemia, one lung was excised and fixed for routine histological evaluation, and the other underwent 
bronchoalveolar vage (BAL). PMN chemotaxis towards the BAL fiuid was then measured using the blindweI1 technique. 
Results: ENO in group 1 increased from 0.9 +_ 0.3 ppb at baseline, to 41.3 +_ 9.2 ppb at the end of ischaemia. Animals in 
this group exhibited significant lung inflammation. Aminoguanidine, dexamethasone a d TNFbp blocked NO production 
(peak ENO values of 7.2 +_ 1.9, 12.6 +_ 1.3 and 8.9 +_ 1.7 ppb for groups 2, 3 and 4 respectively), decreased PMN chemotaxis 
and sequestration in the lung, and attenuated lung inflammation. 
Conclusions: Acute lung injury resulting from distal aortic occlusion starts during ischaemia. TNF and NO blockade 
decrease PMN chemotaxis and sequestration a d attenuate the lung injury process. 
Key Words: Ischaemia; Lung; hlflammation; Neutrophils; TNF; Nitric oxide. 
Introduction 
Acute lung injury is a common complication ofsurgical 
procedures that involve temporary occlusion of the 
aorta with subsequent ischaemia/reperfusion (I/R) of 
the lower extremities. Despite extensive clinical and 
experimental work, the mechanism(s) responsible for 
this injury have not been clearly defined so far. PMNs 
have been shown to have a central role in the lung 
injury process and their depletion, prior to subjecting 
experimental nimals to lower extremity I/R, exerts a 
protective ffect on the lung. 1 The most severe form 
of this injury is the adult respiratory distress yndrome 
(ARDS). In the last decade multiple studies proposed 
that the fundamental pathophysiologic event in ARDS 
is self-induced lung injury. 2 The notion that the host's 
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own immune system mediates the alveolar-capillary 
membrane damage is supported by the observation 
that despite its diverse aetiology, the histologic ap- 
pearance of lung injury in ARDS is remarkably uni- 
form. PMNs are capable of releasing several vasoactive 
and cytotoxic enzymes that can mediate the type of 
injury required to produce ARDS. 2 In many recent 
experimental studies of lower torso ischaemia, it has 
been suggested that acute lung injury occurs after 
reperfusion of the ischaemic lower extremities and is 
due to the release of inflammatory mediators and 
activated inflammatory cells into the systemic cir- 
culation. 1'3-6 The role of ischaemia in the injury process 
has not been adequately examined. 
Endogenous Nitric Oxide (NO) is present in the 
exhaled gas of humans, rats, rabbits and other animals. 7 
NO is synthesised via the oxidation of L-Arginine by 
a family of NO synthases which are either constitutive 
and calcium dependent (cNOS), or inducible and cal- 
cium independent (iNOS). The concentration f NO in 
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the exhaled gas (ENO) increases during inflammatory 
conditions uch as sepsis, ARDS and asthmaY 2The 
increase in ENO is secondary to upregulation of iNOS 
by inflammatory cytokines. 13'14 ENO reflects NO pro- 
duction from the lung, and has been proposed as an 
early index of lung inflammation caused by sepsis. 8
High concentrations of NO, generated by iNOS up- 
regulation, have pro-inflammatory properties and may 
contribute to end organ injury. ~5 
In a recent study, s6 we demonstrated that TNF and 
ENO increase during lower extremity ischaemia nd 
that they both contribute to the resulting acute lung 
injury. We also showed that TNF blockade prevents 
upregulation of NO production and attenuates lung 
injury. In the present study we measured ENO and 
PMN chemotaxis in rats subjected to a 3 h aortic oc- 
clusion, with subsequent lower extremity ischaemia. 
Our hypothesis was that TNF and NO generated 
during acute ischaemia of the lower extremities cause 
increased PMN chemotaxis and sequestration i the 
lung resulting in lung injury. We also studied the effect 
of pharmacologic blockade of TNF and NO on PMN 
chemotaxis and on lung inflammation. 
Materials and Methods 
Animal care complied with the "Principles of Laborat- 
ory Animal Care" as formulated by the National So- 
ciety for Medical Research and the "Guide for the Care 
and Use of Laboratory Animals" (NIH publication o. 
80-23, revised 1985). After approval by the Institutional 
Committee for Human Use of Animals, thirty (30) adult 
male Sprague-Dawley rats weighing 350-450 gm, were 
anesthetised with an intraperitoneal (ip) injection of 
pentobarbital sodium (50 mg/kg). A carotid arterial 
catheter was inserted for systemic arterial pressure 
monitoring, and a jugular venous line was established 
for intravenous (IV) fluid infusion through the same 
neck incision. A tracheostontk/ was then performed 
and the rats were ventilated with room air using a 
rodent ventilator (model 683, Harvard Apparatus, 
South Natick, Mass, U.S.A.). The animals were then 
heparinized (1000 units/kg), and baseline (BL) meas- 
urements of mean arterial pressure (MAP), pulmonary 
airway pressure (Paw) and ENO were obtained. Ap- 
proximately 2ml of blood were withdrawn through 
the arterial line for isolation of unstimulated PMNs 
during baseline conditions. The animals were main- 
tained in anaesthesia with continuous IV infusion of 
pentobarbital sodium at 4 mg/kg/h.  All  animals were 
given Lactated Ringer's solution (Baxters, Deerfield, 
IL) IV, at a constant rate (4 ml/kg/h) during the entire 
course of the experiment. Systemic arterial pressure, 
as well as pulmonary airway pressure, were recorded 
continuously (8890A, Hewlett-Packard Chart recorder, 
Andover, Mass, U.S.A.). 
The infrarenal aorta was exposed through a midline 
abdominal incision and the rats were randomised into 
four groups: 
In group 1 (x-clamp), the aorta was cross-clamped 
just above the bifurcation with special vascular clips 
for 3-h (n = 8). 
In group 2 (AG), 50mg/kg aminoguanidine 
(SIGMA Chemical Company, St Louis, MO), a specific 
iNOS inhibitor, was administered IV prior to the 3 h 
aortic occlusion (n = 6). 
In group 3 (Steroids), l mg/kg dexamethasone 
(American Regent Laboratories, Shirley, NY) was ad- 
ministered IV prior to the 3 h aortic occlusion (n = 8). 
In group 4 (TNFbp), 2 mg/kg TNFbp (a generous 
offer by AMGEN INC, Boulder, CO) was administered 
IV prior to the 3 h aortic occlusion (n = 8). 
MAP, Paw and ENO were measured in 30 min in- 
tervals during the course of the experiment. Arterial 
blood samples were obtained for blood gas analysis 
(ABG) prior to aortic occlusion and hourly thereafter. 
At the end of the experiment, one of the lungs was 
ligated at the hilum and subsequently excised and 
immersion fixed in formalin for histologic evaluation. 
The other lung underwent bronchoalveolar lavage 
(BAL) with 20cc of RPMI 1640 (SIGMA Chemical 
Company, St Louis, MO). Fixed specimens were then 
paraffin embedded, sectioned in 4 g and stained with 
routine haematoxylin-eosin tain. The specimens were 
examined by a pathologist who was blinded to the 
study. Lung injury was rated with a semiquantitative 
score 16 based on congestion, interstitial oedema, PMN 
infiltration and airspace haemorrhage, as follows: 0 = 
no changes, 1+ =focal, mild, subtle changes, 2+ = 
multifocal mild changes, 3 + =multifocal prominent 
changes, and 4 + = extensive prominent changes. The 
number of PMNs per high power field (hpf) was 
measured as an actual index of PMN infiltration for 
statistical purposes. This was done by randomly se- 
lecting five areas of the lung under high power (40 x ) 
magnification, measuring the number of PMNs in each 
area, and calculating the average number of PMNs 
per hpf (PMN/hpf). 
ENO measurement :  ENO was measured using a 
chemiluminescence analyser (Sievers 270 B, Boulder, 
CO). A 1 1 polyvinyl bag was connected to the ex- 
piratory port of the ventilator, and the expiratory gas 
from the rat was collected for 2 min. The bag was then 
connected to the NO analyser and the mean NO 
concentration i  the bag was recorded in parts per 
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billion (ppb) as an index of exhaled NO concentration 
(ENO). ENO was measured prior to aortic occlusion 
(BL) and thereafter in 30 rain intervals for the duration 
of the experiment. The NO analyser was calibrated 
daily using nitrogen for a zero and a mixture of 248 ppb 
NO in nitrogen. Room air was monitored daily and 
when the NO concentration exceeded 5ppb, the rats 
were ventilated with compressed air from a gas cyl- 
inder having zero NO. This insured that the results 
were not influenced by fluctuation in room air NO 
concentration due to environmental factors. Since sev- 
eral other factors (including pH, PEEP and hypoxia) 
also influence ENO, 17 every attempt was made to 
maintain constant conditions during the experiments. 
PMN isolation: 2 ml of blood, obtained through the 
arterial ine at the beginning of the experiment, were 
layered over 3 ml of nycoprep (Life Technologies Inc., 
Gaithersburg, MD) and then purified by dextran sedi- 
mentation and hypotonic lysis of red blood cells. PMNs 
were isolated and suspended at i x 106 cells/ml in 
medium RPMI 1640 containing 0.1% bovine serum 
albumin (BSA), penicillin, streptomycin and glu- 
tamine. PMN viability was >90% in all experiments 
as determined by exclusion of 0.4% trypan blue dye. 
Chemotactic assays: PMN chemotaxis was evalu- 
ated using the blindwell chemotaxis chamber tech- 
nique described by Falk et al. 18 in 1980. In brief, test 
agents (RPMI, FMLP or BAL fluid) were added to the 
lower wells of a 96-well microchemotaxis chamber 
and covered by a 3 pm-pore membrane filter. RPMI 
1640 alone and synthetic FMLP (N-formyl-methionyl- 
leucyl-phenylalanine, SIGMA Chemical Company, St. 
Louis, MO) were used as negative and positive 
chemotactic ontrols respectively. FMLP is a docu- 
mented potent chemoattractant agent for PMNsJ 9 
28 ~L of the PMN suspension was added to the upper 
well of the chemotaxis chamber. Each sample was 
tested in triplicate. The PMNs were allowed to migrate 
for 30 min at 37 ° in an atmosphere of 5% CO2 and 
95% air. Subsequently, the membrane was removed 
and the cells adhering to the top were scraped off 
with a cell scraper. Cells in the bottom well were 
labeled with 3-(4,5-dimethylthiazol-2-yl)-2,5-dip- 
henyltetrazolium bromide (MTT, SIGMA Chemical 
Company, St Louis, MO). Chemotaxis was measured 
by a change in absorbance at 492 nm on a microplate 
reader (Bio/Tek EL-308 microplate reader), and re- 
flected the total number of cells that migrated com- 
pletely through the filter. The cells remaining in the 
bottom well were also microscopically examined to 
ensure staining of PMNs. 
The results are presented as means ± S.]~.M. Statistical 
analysis was performed using analysis of variance 
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Fig. 1. Nitric oxide concentration in exhaled gas (ENO) during aortic 
occlusion. Ingroup i (X-clamp), ENO rose slightly after 1 h ischaemia 
(p<0.05), and continued to rise thereafter (p<0.001 at the end of 
ischaemia). In groups 2 (AG), 3 (Steroids) and 4 (TNFbp) ENO 
increased baseline (p<0.05) after 2.5 h ischaemia. There was no 
significant difference inENO levels among roups 2, 3 and 4 at any 
point during the 3 h ischaemia. In contrast, group 1 ENO was 
significantly higher (p<0.05), compared to the rest of the groups, at 
I h ischaemia, nd for the rest of the experiment. Statistical nalysis 
was performed using ANOVA for repeated measures and Bonferoni 
test for post-hoc paired comparisons. Values are presented as 
mean+s.E.M. (D) X-clamp; (e) AG; (O) steroids; (A) TNFbp. 
(ANOVA) for repeated measures, unpaired student's 
t-test and Bonferoni test for post-hoc paired com- 
parisons; a p value <0.05 was considered significant. 
Results 
The changes in ENO are presented in Fig. 1. Group 1 
(x-clamp) showed a significant increase in ENO that 
started i h after the aorta was clamped, and reached 
a peak value of 41.3+9.2ppb at the end of the ex- 
periment. Groups 2, 3 and 4 exhibited a blunted in- 
crease in ENO which started 2 h after the aortic clamp 
was applied, and continued until the end of the ex- 
periment. Peak ENO values in these groups were 
also detected at the end of the experiment and were 
7.2 + 1.9, 12.6 _+ 1.3 and 8.9 + 1.7 ppb respectively. There 
was no significant difference in ENO levels among 
groups 2, 3 and 4 at any point during the course of the 
experiments. ENO levels in group i were significantly 
higher compared to the other three groups, starting at 
60 min ischaemia, and remained significantly higher 
until the end of the experiment. 
MAP remained stable during the course 'of the ex- 
periment in all four groups. The differences among 
the groups were not statistically significant at any time 
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Fig. 2. Mean arterial pressure (MAP) changes during ischaemia. 
There was no significant change in MAP during the course of the 
experiment in all four groups. There was no significant difference 
in MAP among the groups at any point during the course of the 
experiment. Statistical nalysis was performed using ANOVA for 
repeated measures and Bonferoni test for post-hoc paired com- 
parisons. Results are presented as meanis.mM. ([~) X-clamp; (~) 
AG; (O) steroids; (A) TNFbp. 
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Fig. 3. Changes in pH during ischaemia in the four groups. In 
groups 2, 3 and 4, there was no significant change in the pH during 
the course of the experiment. In contrast, ingroup 1, pH decreased 
significantly (p<0.05) after 3 h ischaemia, ndicating the development 
of metabolic acidosis. Statistical analysis was performed using 
ANOVA for repeated measures and Bonferoni test for post-hoc 
paired comparisons. Results are presented as mean+ S.E.M. ([1) X- 
clamp; (~) AG; (O) steroids; (A) TNFbp. 
point during the experiment (Fig. 2). Paw did not 
change significantly in all groups (data not shown). 
PCO2 gradually decreased and PO2 increased equally 
in all groups, without any significant difference among 
them during the experiment (data not shown). The 
pH remained unchanged throughout the experiments 
in groups 2, 3 and 4. In contrast, in group 1, pH at 
the end of ischaemia was significantly lower (p<0.05) 
compared to the pH in the beginning of the ex- 
periments, indicating the development of metabolic 
acidosis in this group (Fig. 3). 
PMN chemotaxis was significantly different among 
the four groups. BAL fluid from animals in group 1 
exerted a significantly higher degree of PMN chemo- 
taxis compared to each of the other three groups 
(p<0.05). There was no significant difference in PMN 
chemotaxis among groups 2, 3 and 4. All four groups 
exhibited a significantly higher chemotactic activity 
compared to RPMI 1640 (Fig. 4). 
Histologic evaluation revealed different degrees of 
lung inflammation i  the four groups. Groups 2, 3 and 
4 had lesions ranging from 0 to 3+ with average 
injury scores of 2.0, 1.86, and 1.57 respectively. Group 
1 exhibited extensive, prominent histologic changes 
ranging from 1 + to 4 + with average injury score of 
2.63 (Fig. 6). The difference in lung injury score be- 
tween the four groups did not reach statistical sig- 
nificance. However, statistical analysis of the number 
of PMNs per hpf (using student's t-test) revealed that 
at the end of ischaemia, a significantly higher number 
(p<0.05) of PMNs were sequestered in the lungs of the 
animals in group 1 (87.8 +_ 6.4 PMN/hpf )  compared 
to the animals in groups 2 (70.1+4.6PMN/hpf) ,  3 
(71.1+5.6 PMN/hpf )  and 4 (61.0±5.3PMN/hpf) .  
There was no significant difference in the number of 
PMN/hpf  among groups 2, 3 and 4. 
Discuss ion  
Acute lung inflammation is characterised by PMN 
infiltration of the airways and perialveolar space. 
PMNs exist at equilibrium in three separate pools: bone 
marrow, intravascular and interstitial. The pulmonary 
vascular bed is a major PMN reservoir storing 50-60% 
of the total intravascular pool. 2 The current concept is 
that, during inflammation, PMNs are recruited from 
the blood stream by chemotactic factors generated and 
released locally in injured tissues. In the lung, PMNs 
are located in the alveolar capillaries. Subsequent ac- 
tivation of the accumulated PMNs with release of 
vasoactive and cytotoxic molecules may result in ca- 
pillary injury with subsequent enhanced sequestration 
of PMNs in the lung, which lead to ARDS} 
TNF is a known mediator in many inflammatory 
conditions, including sepsis, however its role in lung 
injury is unclear. Experimentally, injection of exo- 
genous TNF causes lung injury characterised by PMN 
sequestration in pulmonary microvasculature, in- 
creased endothelial permeability and interstitial oed- 
ema.  2°'21 These changes resemble those seen after lower 
extremity I/R. 3 Both injuries are PMN dependent and 
can be prevented by prior depletion of circulating 
PMNs. 21 This is indirect evidence of an in vivo link 
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Fig. 4. PMN chemotaxis, measured as absorption at 492 nm (see text). BAL fluid from all four groups exhibited significantly higher degree 
of PMN chemotaxis (p<0.01) compared to RPMI. BAL fluid from group 1 was significantly more chemotactic for PMNs (p<0.05) compared 
to every other group. There was no significant difference on PMN chemotaxis between groups 2, 3 and 4. Statistical nalysis was performed 
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Fig. 5. Number of PMNs per hpf at the nd of ischaemia. Group 1 
lungs exhibited a significantly higher degree of PMN sequestration 
(p<0.05) compared to every other group. There was no significant 
difference in PMN sequestration between groups 2, 3 and 4. Stat- 
istical analysis was performed using unpaired Student's t-test. 
Results are presented as me n--S.E.M. 
between TNF and PMN-mediated inflammation. 
Sternbergh etal. 22 using isolated rat hindlimbs, showed 
that TNF is generated by isolated lower extremities 
subjected to ischaemia. In a previous study, 16 we ob- 
served a significant rise in serum TNF concentration 
during the first hour of lower extremity ischaemia. 
Peak TNF concentration i these animals was meas- 
ured 60 min after the aortic clamp was applied and 
by the end of the 3 h ischaemia, TNF returned to 
baseline value and remained low during reperfusion. 
In the present study we demonstrated that this increase 
in serum TNF induces significant PMN chemotaxis 
and sequestration i the lung during ischaemia, with 
subsequent lung inflammation. The significant role of 
TNF in this process is supported by the fact that its 
selective blockade by TNFbp results in significant 
attenuation of PMN chemotaxis and lung injury. Sev- 
eral other investigators have reported that TNF is a 
chemotactic factor for PMNs. 23-25 Smart and Casale 26 
also showed that TNF induces IL-8 production by 
endothelial cells, which greatly facilitates PMN mi- 
gration through endothelial layers. TNF generated at 
the site of inflammation, not only attracts PMNs but 
also upregulates the expression of CD11b/CD18 com- 
plex. 27 Increased expression of these surface antigens 
significantly increases PMN adhesion and se- 
questration at the site of inflammation. 
In addition, TNF acts synergistically with other cyto- 
kines to cause upregulation of iNOS and increased NO 
production by pulmonary endothelial and bronchial 
epithelial cells in culture. 13 We found that lower ex- 
tremity ischaemia causes a significant increase in NO 
production by the lung which is due to upregulation 
of iNOS. This increased NO production by the lung 
appears to play a significant role in the development 
of inflammation, and its selective inhibition by amino- 
guanidine results in decreased PMN chemotaxis and 
subsequently in a lesser degree of lung injury. Our 
results are in agreement with several in vitro chemo- 
tactic studies. Specifically, Belenky et ~/l. 28'29 showed that 
NOS inhibitors attenuate human PMN and monocyte 
chemotaxis towards other known chemotactic factors 
(FMLP, LTB4, etc). This action is associated with a 
decreased production of intracellular c-GMP and can 
be reversed by the addition of NO precursors (L- 
arginine, sodium nitroprusside), indicating that endo- 
genous production of NO is important in regulating 
PMN locomotion. Similar results have been reported 
previously by Kaplan et al. 3° Recently, Beauvais et al. 31 
showed that exogenous NO also elicits PMN chemo- 
taxis in vitro. It should be mentioned, however, that 
there is significant controversy in current literature 
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Fig. 6. Distribution of lung injury scores in the four groups. Animals in group 1 exhibited the most severe histologic lung changes at the 
end of the experiment, whereas aminoguanidine, dexamethasone and TNFbp had a protective ffect. 
concerning the role of NO in inflammatory conditions. 
NO has been reported to inhibit PMN aggregation 15's2 
and their adhesion to endothelium, Is'g3'34 a step required 
early in the development of PMN mediated in- 
flammatory processes. In addition NO has also been 
shown to inhibit the production of O 2-  by activated 
PMNs. 32'35 Nevertheless, our results clearly suggest that 
decreased NO production isassociated with decreased 
PMN chemotaxis and, subsequently, with lesser degree 
of lung injury, regardless which agent is used to inhibit 
its production (aminoguanidine, dexamethasone or 
TNFbp). Moreover, the fact that inhibition of NO 
production by aminoguanidine decreases PMN 
chemotaxis, despite the presence of increased serum 
TNF concentration, raises the question if NO pro- 
duction is required for PMN chemotaxis and se- 
questration in the lung during inflammatory 
conditions. Although our results indirectly suggest 
this as a possible mechanism, further studies will be 
needed to clearly prove this hypothesis. 
In conclusion, inflammatory changes in the lung, 
resulting from temporary occlusion of the aorta, start 
during ischaemia and are characterised by PMN 
chemotaxis and sequestration i  the lung, congestion 
and interstitial oedema. TNF is generated in the early 
phase of lower extremity ischaemia, followed by a 
gradual increase in NO production, and they both 
appear to play a significant role in the development of 
acute lung injury. Selective blockade of these molecules 
results in decreased PMN chemotaxis and, sub- 
sequently, in lesser degree of lung inflammation. 
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